Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $180.02, marking a -0.49% move from the previous day.
Voyager (VYGR) Surges on Gene Therapy Deal With Pfizer
by Zacks Equity Research
Voyager (VYGR) signs agreement with Pfizer granting the latter with rights to develop novel capsids using Voyager's proprietary technology for Pfizer's gene therapies and options for exclusive license to the capsids.
Here's Why You Should Hold on to Illumina (ILMN) for Now
by Zacks Equity Research
Investors are optimistic about Illumina (ILMN) owing to its strategic partnerships and wider market adoption of its products.
Abbott (ABT) Gets FDA Nod for Amplatzer Talisman System
by Zacks Equity Research
The Amplatzer Talisman PFO Occlusion System from Abbott (ABT) is used to treat patients with a patent foramen ovale and are at risk of recurrent ischemic stroke.
Here's Why You Should Retain Myriad Genetics (MYGN) for Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics (MYGN) owing to strong testing volume growth and notable product launches.
Alcon's (ALC) Robust Product Line, Market Rebound Aid Growth
by Zacks Equity Research
In Presbyopia-correcting Intraocular Lens (PCIOLs), Alcon (ALC) currently leads the market with over 55% of global share and over 80% share in the United States.
Vertex Pharmaceuticals (VRTX) Stock Moves -0.46%: What You Should Know
by Zacks Equity Research
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $181.38, marking a -0.46% move from the previous day.
Seagen (SGEN) Completes Enrollment in Colorectal Cancer Study
by Zacks Equity Research
Seagen (SGEN) enrolls the last patient in the phase II MOUNTAINEER study evaluating Tukysa in combination with Herceptin, and as a single agent for treating HER2-positive metastatic colorectal cancer.
Evelo (EVLO) Posts Positive Data from Phase II Psoriasis Study
by Zacks Equity Research
Evelo Biosciences (EVLO) reports encouraging data from a phase II study evaluating EDP1815 for the treatment of mild and moderate psoriasis. Shares up in pre-market trading.
Ultragenyx (RARE) Reports FDA Removal of Clinical Hold on Study
by Zacks Equity Research
Ultragenyx (RARE) and GeneTx Biotherapeutics to start dosing in the phase I/II study on GTX-102 for treating pediatric patients with Angelman syndrome after the FDA removes its clinical hold on the same.
FDA Accepts Bristol Myers (BMY) sBLAs for Opdivo Combo for ESCC
by Zacks Equity Research
The FDA accepts Bristol Myers' (BMY) sBLAs for Opdivo-based combinations as a potential treatment for esophageal squamous cell carcinoma.
Dare (DARE) Begins Study to Treat Vulvar and Vaginal Atrophy
by Zacks Equity Research
Dare Bioscience (DARE) starts a phase I/II study to evaluate DARE-VVA1 to treat moderate to severe vulvar and vaginal atrophy.
The Zacks Analyst Blog Highlights: Disney, Adobe, Wells Fargo, IHS Markit and Vertex Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Disney, Adobe, Wells Fargo, IHS Markit and Vertex Pharma
Zacks Value Investor Highlights: Nu Skin Enterprises, VF Corp, Yamana Gold, Meritor and Vertex Pharmaceuticals
by Zacks Equity Research
Zacks Value Investor Highlights: Nu Skin Enterprises, VF Corp, Yamana Gold, Meritor and Vertex Pharmaceuticals
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $185.09 in the latest trading session, marking a +0.44% move from the prior day.
Top Analyst Reports for Disney, Adobe & Wells Fargo
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Walt Disney Company (DIS), Adobe Inc. (ADBE), and Wells Fargo & Company (WFC).
5 Top Ranked Stocks on Sale Right Now
by Tracey Ryniec
These stocks are disconnected from their earnings outlook as the analysts remain bullish but the Street is bearish.
VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
VRTX vs. PRTA: Which Stock Is the Better Value Option?
4 Top Biotech Stocks to Watch as Economic Recovery Picks Up Pace
by Ekta Bagri
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position REGN, MRNA, VRTX, and HZNP well amid the economic recovery.
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer (Revised)
by Zacks Equity Research
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
AbbVie (ABBV) Files for Skyrizi in Crohn's Disease With FDA
by Zacks Equity Research
AbbVie (ABBV) submits a regulatory application in the United States, seeking approval for Skyrizi in Crohn's disease.
Seagen (SGEN) Gets Early FDA Nod for Tivdak in Cervical Cancer
by Zacks Equity Research
The FDA grants accelerated nod to Seagen (SGEN) and Genmab's Tivdak for treating adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Verrica (VRCA) Gets CRL From the FDA for Skin Disease Drug
by Zacks Equity Research
Verrica (VRCA) suffers a setback yet again as the FDA issues a CRL for its lead product candidate VP-102. Consequently, shares are trading down.
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $188.30 in the latest trading session, marking a +0.64% move from the prior day.
Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study
by Zacks Equity Research
Biogen (BIIB) reports mixed data from the phase II study evaluating its non-opioid pain candidate vixotrigine for treating small fiber neuropathy.